
USD
$0.00
(0.00%
)At Close (As of Oct 24, 2025)
$105.48M
Market Cap
-
P/E Ratio
-1.24
EPS
$10.24
52 Week High
$4.65
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $3.6M |
| Total Revenue | $3.6M |
| Cost Of Revenue | $27K |
| Costof Goods And Services Sold | $27K |
| Operating Income | -$17M |
| Selling General And Administrative | $8.9M |
| Research And Development | $12M |
| Operating Expenses | $21M |
| Investment Income Net | - |
| Net Interest Income | - |
| Interest Income | - |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $27K |
| Income Before Tax | -$16M |
| Income Tax Expense | -$720K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$15M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$17M |
| Ebitda | -$17M |
| Net Income | -$15M |
| Field | Value (USD) |
|---|---|
| Total Assets | $44M |
| Total Current Assets | $44M |
| Cash And Cash Equivalents At Carrying Value | $38M |
| Cash And Short Term Investments | $38M |
| Inventory | - |
| Current Net Receivables | $731K |
| Total Non Current Assets | $39K |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $38B |
| Other Current Assets | -$38B |
| Other Non Current Assets | - |
| Total Liabilities | $4.8M |
| Total Current Liabilities | $3.8M |
| Current Accounts Payable | $1.6M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | - |
| Total Non Current Liabilities | $945K |
| Capital Lease Obligations | - |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | - |
| Other Current Liabilities | $1.4M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $40M |
| Treasury Stock | - |
| Retained Earnings | -$41B |
| Common Stock | $1.7K |
| Common Stock Shares Outstanding | $15M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$10M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $27K |
| Capital Expenditures | $0 |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | -$25K |
| Cashflow From Financing | $16M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$15M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $3.6M |
| Total Revenue | $3.6M |
| Cost Of Revenue | $27K |
| Costof Goods And Services Sold | $27K |
| Operating Income | -$17M |
| Selling General And Administrative | $8.9M |
| Research And Development | $12M |
| Operating Expenses | $21M |
| Investment Income Net | - |
| Net Interest Income | - |
| Interest Income | - |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $27K |
| Income Before Tax | -$16M |
| Income Tax Expense | -$720K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$15M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$17M |
| Ebitda | -$17M |
| Net Income | -$15M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Coya Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Houston, Texas, dedicated to developing innovative therapies that enhance the effectiveness of regulatory T cells (Tregs) for the treatment of autoimmune and neurodegenerative diseases. With a proprietary platform, Coya is advancing its pipeline towards critical indications such as Multiple Sclerosis and Amyotrophic Lateral Sclerosis, positioning itself as a leader in Treg modulation. As the company progresses its clinical programs, it stands to make substantial contributions to the future of immune-mediated therapies, addressing significant unmet medical needs in the field.